Clin2
NCT07737990Possibly a fitEnrolling by invitation

Psilocybin group therapy for treatment-resistant depression

Treatment-resistant Depression (TRD)

Part of Mental health clinical trials.

This trial tests whether psilocybin-assisted group therapy can help people whose depression hasn't improved with other treatments. You must have already completed a prior psilocybin study to join this group.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
65 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have completed a specific previous trial that tested psilocybin (PSI-1V2 or Psilo-BD).
  • You must be willing to attend all group therapy sessions and keep other group members' information private.
  • You cannot have active suicidal thoughts or plans.
  • You must be able to read and speak English well enough to understand the study materials and take part in group discussions.
  • You cannot be receiving psilocybin-assisted therapy elsewhere during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07210112Not yet recruiting· Phase 2
Psilocybin and Trazodone for tough-to-treat depression

This trial tests if taking psilocybin (a psychedelic drug) with trazodone (an antidepressant) can help people whose depression hasn't improved with at least two standard antidepressants. If you have treatment-resistant depression, this study might be an option.

Paris
NCT06512220Recruiting· Phase 2
Psilocybin for treatment-resistant depression brain imaging study

This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.

Toronto, Ontario
NCT07211438Recruiting· Phase 2
Psilocybin with Monitors for Treatment-Resistant Depression

This study tests whether trained monitors improve the safety and outcomes of psilocybin therapy for people with depression that hasn't responded to other treatments. Participants will receive psilocybin in a supervised setting and will need to temporarily stop other psychiatric medications.

Toronto, Ontario
NCT06072898Recruiting· Phase 2
Psilocybin brain imaging trial for depression

This study tests whether a single dose of psilocybin (a psychedelic compound) can help treat depression by looking at brain changes on MRI. It is designed for people with moderate-to-severe depression who have not responded well to other treatments.

Toronto, Ontario
NCT07405606Not yet recruiting· Phase 2
Psilocybin therapy for depression and alcohol use disorder

This study tests whether a drug called psilocybin, given along with therapy, can help people who have both major depression and alcohol use disorder. You may be a good fit if you have tried other treatments or don't want to start new medications.

Toronto, Ontario
NCT07183748Recruiting· Phase 2
Psilocybin microdosing plus therapy for hard-to-treat depression

This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.

Beersheba

Hear when a new Treatment-resistant Depression (TRD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.